XML 37 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Liquidity (Details)
 1 Months Ended 3 Months Ended 4 Months Ended 6 Months Ended
Apr. 25, 2019
USD ($)
Apr. 24, 2019
USD ($)
Sep. 21, 2018
USD ($)
Aug. 28, 2018
$ / shares
Jul. 25, 2018
USD ($)
$ / shares
shares
Jun. 01, 2018
USD ($)
May 23, 2018
shares
Aug. 31, 2019
$ / shares
Jun. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
shares
Jun. 30, 2018
USD ($)
shares
Mar. 31, 2018
USD ($)
shares
Dec. 31, 2018
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Jun. 30, 2018
USD ($)
May 24, 2018
shares
Dec. 31, 2017
USD ($)
Liquidity [Line Items]                                  
Loss from continuing operations                 $ 2,267,000   $ 2,285,000     $ 4,729,000 $ 5,472,000    
Accumulated deficit                 (426,680,000)       $ (414,383,000) $ (426,680,000)      
Substantial doubt about going concern, description                           These factors raise substantial doubt about our ability to continue as a going concern.      
Cash and cash equivalents                 4,530,000       5,261,000 $ 4,530,000      
Minimum cash/cash equivalents covenant                 2,000,000         2,000,000      
Proceeds from sale of common stock, net                           1,984,000 (200,000)    
Common stock issued (in shares) | shares         6,723                        
Number of shares callable by warrants (in shares) | shares             23,400,000                 2,300,000  
Proceeds from issuance warrants         $ 5,700,000                        
Reverse stock split of common stock             0.1                    
Stockholders’ equity (deficit)                 (6,276,000) $ 3,857,000 4,751,000 $ 8,480,000 5,225,000 (6,276,000) 4,751,000   $ 13,000,000
Common stock issued, value                 64,000 $ 1,873,000 $ (297,000) $ 27,000          
Cash proceeds from sale of subsidiary                           2,789,000 $ 0    
UK Subsidiary and Cell Therapy Assets [Member]                                  
Liquidity [Line Items]                                  
Cash proceeds from sale of subsidiary   $ 3,400,000                              
UK Subsidiary and Cell Therapy Assets [Member] | Amendment to Loan and Security Agreement [Member]                                  
Liquidity [Line Items]                                  
Payments for principal, interest and fees   $ 1,700,000                              
Japanese Subsidiary and Cell Therapy Assets [Member]                                  
Liquidity [Line Items]                                  
Cash proceeds from sale of subsidiary $ 2,500,000                                
Japanese Subsidiary and Cell Therapy Assets [Member] | Amendment to Loan and Security Agreement [Member]                                  
Liquidity [Line Items]                                  
Payments for principal, interest and fees $ 1,400,000                                
Nasdaq Stock Market LLC [Member]                                  
Liquidity [Line Items]                                  
Number of consecutive business days no longer able to meet the required closing bid price of common stock       30 days                          
Minimum bid price of common stock required for Nasdaq listing rule | $ / shares       $ 1.00                          
Grace period provided with minimum bid price for Nasdaq listing rule       180 days                          
Grace date for minimum bid price requirement for Nasdaq listing       Feb. 25, 2019                          
Common stock minimum bid price required to regain compliance | $ / shares       $ 1.00                          
Number of consecutive business days required to regain compliance       10 days                          
Date to regain compliance after meeting continued listing requirement       Aug. 26, 2019                          
Additional grace period provided with minimum bid price to regain compliance       180 days                          
Stockholders’ equity (deficit)                 (6,300,000)         (6,300,000)      
Minimum stockholders equity requirement                 $ 2,500,000         $ 2,500,000      
Description of compliance with minimum bid price requirement                           We were also granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.      
Nasdaq Stock Market LLC [Member] | Forecast [Member]                                  
Liquidity [Line Items]                                  
Reverse stock split of common stock               0.02                  
Minimum bid price of common stock required for Nasdaq listing rule | $ / shares               $ 1.00                  
Series C Convertible Preferred Stock [Member]                                  
Liquidity [Line Items]                                  
Number of convertible shares converted into common stock (in shares) | shares         200,000                        
Number of shares callable by warrants (in shares) | shares         7,059,150                        
Common Stock [Member]                                  
Liquidity [Line Items]                                  
Common stock issued (in shares) | shares         6,723       5,000 139,855 192 202          
Number of shares callable by warrants (in shares) | shares         141,183                        
Warrant exercise price (in dollars per share) | $ / shares         $ 39.93                        
Common Stock [Member] | Series C Convertible Preferred Stock [Member]                                  
Liquidity [Line Items]                                  
Number of convertible shares converted into common stock (in shares) | shares                   1,653              
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]                                  
Liquidity [Line Items]                                  
Remaining availability under financing facility                 $ 0         $ 0      
Common Stock [Member] | Lincoln Park [Member]                                  
Liquidity [Line Items]                                  
Proceeds from sale of common stock, net                         $ 300,000 $ 100,000      
Common stock issued (in shares) | shares                         12,802 5,000      
Common stock issued, value     $ 5,000,000                            
Period exercisable from the date of issuance     24 months                            
Minimum [Member]                                  
Liquidity [Line Items]                                  
Unrestricted cash and cash equivalents                 2,000,000         $ 2,000,000      
Maximum [Member] | Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]                                  
Liquidity [Line Items]                                  
Proceeds from sale of common stock, net           $ 6,500,000                      
Maximum [Member] | Common Stock [Member] | Lincoln Park [Member]                                  
Liquidity [Line Items]                                  
Remaining availability under financing facility                 $ 100,000         $ 100,000